SELLAS Life Sciences reports 'promising' cancer vaccine PhII data; Aridis Pharmaceuticals gets NIH grant to develop vaccine storage tech;

> SELLAS Life Sciences announced that in a Phase II study of its WT1 cancer vaccine in malignant pleural mesothelioma patients, top-line data demonstrated clinical significant increases in overall survival and progression-free survival. Release

> Aridis Pharmaceuticals announced that it has received several National Institutes of Health grants, one of which is to develop technology to encase proteins into room temperature stable formulations for simpler vaccines storage. Release

> An attempt to repeal California's strict vaccination requirements for schoolchildren fell short of signatures. More

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.